Peg L-AsparaginaseThird Party Manufacturing in India

Peg L-Asparaginase works by catalyzing the cleavage of systemic L-asparagine into aspartic acid and ammonia. Leukemic cells lack the enzyme asparagine synthetase and rely on circulating exogenous L-asparagine for protein synthesis, leading to cellular starvation and death when depleted. Unlike native bacterial asparaginase, the covalent attachment of polyethylene glycol blocks immunogenic epitopes, extending the plasma half-life and lowering the frequency of hypersensitivity reactions. It is highly effective and well-tolerated in pediatric and adult leukemia protocols.

Therapeutic Uses

• Acute Lymphoblastic Leukemia: Integral component of multi-agent chemotherapy regimens for first-line treatment.
• NK/T-cell Lymphoma: Used as part of specialized therapeutic combinations for aggressive extranodal variants.

Why Manufacturers Choose Peg L-Asparaginase

This pegylated biological entity presents unique manufacturing complexities that deter general formulation companies. Peg L-Asparaginase third party manufacturing in India requires precise macromolecular handling and specialized lyophilization capabilities to retain enzymatic activity under CAS 9015-68-3. Our partner network features cold-chain logistics integrated directly into operational setups, where our production facilities are WHO-GMP certified for sterile biological processing. We provide distributors with a reliable procurement route for this high-value asset, ensuring compliance with strict international biological regulations.